The U.S. Department of Health and Human Services (HHS) is considering creating two new deputy commissioner positions within the Food and Drug Administration (FDA), according to multiple reports. One would focus on technology and artificial intelligence, while the other would oversee drugs.
No final decisions have been made, and the process is described as still in planning. CNBC reports that two sources familiar with the matter say HHS plans to name the two deputy commissioners, without specifying a timeline or confirmed staffing details. Quartz similarly reports that HHS is planning the roles, including one dedicated to technology and AI, and notes that outcomes have not yet been finalized.
The outlets do not present competing factual claims about the core structure of the proposed leadership changes; the main difference is the level of detail each source provides and how it characterizes the certainty of the plan. Both accounts frame the proposal as under consideration rather than an already implemented reorganization.
